DPP4
- Known as:
- DPP4
- Catalog number:
- 80040
- Product Quantity:
- 10 µg
- Category:
- -
- Supplier:
- BPS Bioscience
- Gene target:
- DPP4
Related genes to: DPP4
- Gene:
- DPP4 NIH gene
- Name:
- dipeptidyl peptidase 4
- Previous symbol:
- CD26, ADCP2
- Synonyms:
- DPPIV
- Chromosome:
- 2q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-03-05
- Date modifiied:
- 2016-02-05
Related products to: DPP4
Related articles to: DPP4
- Selective elimination of senescent hepatocytes by DPP4-CAR-NK cells could rescue liver fibrosis; therefore improving liver function and metabolic homeostasis in CCl-induced liver fibrotic and naturally aged mice. - Source: PubMed
Publication date: 2026/07/01
Hua RuiXu KangPeng HuanLiu KundaLong NanZeng ChenyeWang YidaGuo YannanWang Zhao - Cannabis sativa, a medicinal plant rich in cannabinoids, terpenoids, and flavonoids, has been shown to have various pharmacological activities. This study investigated the antidiabetic potential of C. sativa inflorescence extracts using in vitro and computational models. Dried C. sativa inflorescences were extracted sequentially with hexane, dichloromethane, and methanol, before their metabolites were identified by GC-MS. The extracts were tested for α-amylase and α-glucosidase inhibition, glucose uptake activity, and antioxidant effects using DPPH and nitric oxide (NO) inhibition assays. Thirty-six metabolites were further docked against diabetes-related proteins. Among the extracts, the hexane extract showed the strongest bioactivity with notable α-amylase inhibition (IC: 727 µg/mL), DPPH free radical scavenging (IC: 478.62 µg/mL), and nitric oxide inhibition activity (IC: 356.51 µg/mL). Docking analyses revealed strong binding affinities for 8-hydroxy-delta-9-THC, cannabivarin, and 9-tetrahydrocannabinol with DPP-4, PTP1B, and other target proteins. These findings highlight the potential of C. sativa inflorescences as a source of antidiabetic agents, warranting further in vivo and clinical validation. - Source: PubMed
Chinheya Rosa MNgoungoure Viviane L NAli IbeabuchiOlofinsan KolawoleJim TseboTankeu FrancineMatsabisa Motlalepula G - - Source: PubMed
Publication date: 2026/09/19
Odic PierreNardi OlivierFoucault-Fruchard Laura - This study investigated the DPP-4 inhibitory and insulin signaling modulating activities of (rhinoceros beetle) larval protein hydrolysate. Following enzymatic hydrolysis, three fractions were obtained by HPLC fractionation. Among them, fraction 3 (F3) exhibited the strongest dipeptidyl peptidase-4 (DPP-4) inhibitory activity (IC: 0.72 mg/mL). In an insulin-resistant HepG2 cell model, F3 significantly increased glucose uptake and enhanced Akt phosphorylation at Thr308, along with upregulation of GLUT4 expression, indicating improved insulin signaling responses. Furthermore, LC-MS/MS analysis identified 22 compounds enriched in hydrophobic and aromatic amino acids within F3. Molecular docking analysis predicted that these compounds interact with key DPP-4 active-site residues, including Glu205/Glu206, Tyr547, and Tyr662. Additionally, quantitative analysis revealed substantial levels of Trp, Val-Leu, and Met-Leu, which have previously been reported as DPP-4 inhibitory compounds. Collectively, these findings suggest that larval hydrolysate contains bioactive peptides with DPP-4-inhibitory and insulin-signaling-modulating properties, supporting its potential for glucose homeostasis. - Source: PubMed
Publication date: 2026/06/22
Han Jae HeeAuh Joong-Hyuck - To systematically compare sodium-glucose linked transporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP4i) in glycemic control, weight reduction and genital infection risk in type 2 diabetic patients, and provide evidence-based support for individualized clinical medication. - Source: PubMed
Publication date: 2026/09/04
Fang XiancongLi RongLiu ShengbinZou XiaominZhong YanlingYang Yalun